Nuveen LLC Makes New $833.94 Million Investment in Danaher Corporation (NYSE:DHR)

Key Points

• Nuveen LLC has invested approximately $833.94 million in Danaher Corporation, acquiring over 4 million shares, which represents about 0.57% ownership in the company.
• Danaher’s Chairman, Steven M. Rales, sold 1.25 million shares of the company's stock for a total of $245.93 million, reducing his ownership by 28.70%.
• The stock has recently reported a 1.1% increase, with a current market cap of $143.71 billion, and posted stronger than expected earnings of $1.80 EPS for the last quarter.

Nuveen LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,068,007 shares of the conglomerate's stock, valued at approximately $833,941,000. Nuveen LLC owned 0.57% of Danaher as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. grew its position in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the period. Heck Capital Advisors LLC acquired a new position in Danaher during the fourth quarter worth about $27,000. Sierra Ocean LLC boosted its position in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Danaher during the first quarter worth about $31,000. Finally, Dunhill Financial LLC boosted its position in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Up 3.0%

Shares of DHR stock traded up $6.03 during trading on Tuesday, reaching $205.79. The company's stock had a trading volume of 2,829,956 shares, compared to its average volume of 4,735,438. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market capitalization of $147.36 billion, a price-to-earnings ratio of 43.79, a P/E/G ratio of 2.79 and a beta of 0.73. The stock's 50-day moving average price is $198.95 and its 200 day moving average price is $200.34. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.72 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Robert W. Baird boosted their target price on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Evercore ISI decreased their target price on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Guggenheim reiterated a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.